Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Study Overview
=================
Brief Summary
-----------------
This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Detailed Description
-----------------
Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Official Title
-----------------
Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Conditions
-----------------
Type 2 Diabetes, Insulin Resistance, Obesity, Nesfatin-1

Intervention / Treatment
-----------------
* Diagnostic Test: Nesfatin-1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes Insulin resistance Obesity disease Exclusion Criteria: Pediatric individuals All patients who are hospitalized, Liver disease Cancer patients Disease related to the gastrointestinal tract Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome Neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Type 2 Diabetes group<br>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1. | Diagnostic Test: Nesfatin-1<br>* Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level<br>|
| Other: Insulin resistance group<br>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1. | Diagnostic Test: Nesfatin-1<br>* Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level<br>|
| Other: Obesity group<br>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1. | Diagnostic Test: Nesfatin-1<br>* Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nefratin-1 in type 2 diabetes | Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45) | 1 day (Blood will be drawn from patients once) | 
| Nefratin-1 in obesity | Blood will be drawn from obesity patients after 12 hours of fasting (n=45) | 1 day (Blood will be drawn from patients once) | 
| Nefratin-1 in insulin resistance | Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45) | 1 day (Blood will be drawn from patients once) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes, Insulin resistance, Obesity, Nesfatin-1